Chiusura precedente | 178,45 |
Aperto | 183,00 |
Denaro | N/D x N/D |
Lettera | N/D x N/D |
Min-Max giorno | 175,80 - 183,00 |
Intervallo di 52 settimane | 144,81 - 207,67 |
Volume | |
Media Volume | 266 |
Capitalizzazione | 86,15B |
Beta (5 anni mensile) | 0,29 |
Rapporto PE (ttm) | 34,47 |
EPS (ttm) | 5,10 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | 2,46 (1,40%) |
Data ex dividendo | 11 mar 2024 |
Stima target 1A | N/D |
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL BehringLEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the achievement of a $100 million milestone associated with the first commercial sale of HEMGENIX® in the United States by its partner, global biotechnology leader CSL (ASX: CSL). HEMGENIX® (etranacoge
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysisST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recomme